Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients

Launched by TANTA UNIVERSITY · Mar 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the safety and effectiveness of a medication called carbocisteine for people with Non-Alcoholic Fatty Liver Disease (NAFLD). NAFLD is a condition where fat builds up in the liver without being caused by alcohol, and it can lead to serious liver problems. The trial is currently recruiting participants aged 18 and older who have been diagnosed with fatty liver through an ultrasound. However, individuals who are pregnant, drink excessive alcohol, have other liver diseases, or certain health conditions like chronic kidney disease will not be eligible to join.

Participants in this trial will have the chance to take carbocisteine and help researchers understand how well it works for treating NAFLD. Throughout the trial, participants will be monitored closely for their health and any side effects. This study is important because it could lead to new treatments for a condition that affects many people worldwide. If you or someone you know may be interested, it’s a good idea to talk to a healthcare provider for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Either male or female adult patients (\>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography
• Exclusion Criteria:
• • Pregnant and/or lactating women
• • Excessive alcohol use (defined as an average alcohol intake \> 30 g per day in men and \> 20 g per day in women)
• • Other etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, autoimmune hepatitis.
• • patients suffering from chronic kidney disease, and hyper/hypoparathyroidism
• • Hypersensitivity to carbocistiene.